Last updated 2026-09-04
- Sells NeuroNOS Stake to UNIVO Pharmaceutical Industries, Aug 2026
- Went public on NASDAQ (XAIR), May 2019
- Raised $50M Follow-on PO, Mar 2024
Total raised
$246.0M
Last: PIPE 2026-01
Stage
Public
Founded
2011
Headcount
54
HQ
Garden City, United States
Sector
Healthcare
About
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patient outcomes in respiratory illnesses, neurological disorders, and solid tumors. The company's LungFit platform generates NO from ambient air, eliminating the need for cylinders. Its products include LungFit PH, approved for persistent pulmonary hypertension of the newborn, and investigational systems for viral lung infections and nontuberculous mycobacteria. Through its affiliate, Beyond Cancer, Ltd., the company is also developing ultra-high concentration nitric oxide for solid tumors.
Funding history · 13 rounds · $246.0M total
16 events/rounds · $246.0M Total Funding: $30.0M in Private Equity, $202.8M in Public Equity, $41.0M in Debt
Jul 2026
PIPE
$10.2M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jan 2026
PIPE
$5.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Dec 2025
Follow-on PO
$20.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Nov 2025
Debt Financing
$12.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Sep 2025
Follow-on PO
$3.2M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Nov 2024
Debt Financing
$11.5M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Sep 2024
PIPE
$20.6M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Mar 2024
Follow-on PO
$50.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Mar 2024
Follow-on PO
$16.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jun 2023
Debt Financing
$17.5M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2022
Follow-on PO
$50.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Nov 2021
★ certain institutional and/or accredited investors
Feb 2021
Grant
Undisclosed
tracxn.com
★ Cystic Fibrosis Foundation
Headcount over time
54 employees (2026-09) · 1 point
Offices
Garden City, United States · HQ / main office
Q&A
- What was Beyond Air's revenue growth for the fiscal year ending March 31, 2025?
- Beyond Air reported a 220% increase in revenue for the fiscal year ending March 31, 2025, reaching $3.7 million.
- What is the status of Beyond Air's second-generation LungFit PH system?
- Beyond Air submitted a PMA supplement application to the FDA for its second-generation LungFit PH II system in June 2025. The company anticipates FDA approval by the end of 2026.
- What recent financing did Beyond Air secure in November 2025?
- In November 2025, Beyond Air secured a $12 million promissory note and a $20 million equity line of credit from Streeterville Capital, expected to extend its cash runway into 2027.
- What is the latest development regarding Beyond Air's NeuroNOS subsidiary?
- In January 2026, XTL Biopharmaceuticals Ltd. announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, for up to $32.5 million, marking XTL's entry into the autism therapeutics market. However, in March 2026, Beyond Air announced the termination of the agreement to sell its NeuroNOS subsidiary to XTL Biopharmaceuticals Ltd.
- Has Beyond Air expanded its international distribution for LungFit PH recently?
- Yes, in December 2025, Beyond Air expanded its distribution network for LungFit PH to 39 countries, including Germany, Brazil, Austria, the Netherlands, and Sri Lanka.
- What is the status of Beyond Air's LungFit PH system in Australia?
- In January 2025, Beyond Air's LungFit PH device received market authorization from the Australian Therapeutic Goods Administration (TGA) as a Class IIb medical device.
- What is the current employee count for Beyond Air?
- Beyond Air has 51-200 employees.
- What is Beyond Air's primary focus as a company?
- Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patient outcomes in respiratory illnesses, neurological disorders, and solid tumors.
Team · 13
Yossef Av-Gay
Founder · Board Member
Robert Goodman
CEO and Board Director
Dan Moorhead
Chief Financial Officer
Frederick Montgomery, PhD
Vice President, Medical Systems
Michael Gaul
Chief Operating Officer
John Jett, PhD
Head of Research and Clinical Development
Robert F. Carey
Chairman of the Board
Erick Lucera
Director
Yoori Lee
Director
Bill Forbes, PharmD
Director
Andrew Colin
Board Member
Roger Kornberg
Board Member
David Greenberg
Board Member
Sectors & technology
Primary sector
Healthcare
Technologies
Target customers
Business model
B2BB2C
Highlights
1 Patents
Tags
medical-deviceschronic-diseaserespiratoryasthmainfectionpharmaceuticalspulmonaryinhalationchronic-patients
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | beyondair.net/ |
|---|---|
| linkedin.com/company/5256195 | |
| Crunchbase | crunchbase.com/organization/ait |
Identifiers & details
| Legal name | Beyond Air, Inc. |
|---|---|
| Former names | Advanced Inhalation Therapies |
| Founded | 2011 |
| Employees (exact) | 54 |
| Offices | Garden City |
| Market cap | $5.8M |
| Status reason | Public on NASDAQ on Aug, 2015 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2019-05 | NASDAQ | XAIR | $330K |
| Public Offering | 2019-12 | NASDAQ | XAIR | $11.5M |
| Public Offering | 2024-03 | NASDAQ | XAIR | $16.0M |
Radar intelligence
Patents
| EPO | 18 |
|---|
Web history (Wayback)
| Domain | beyondair.net |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514609387 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2011-05-01 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | הורביץ אלי 12 רחובות |